Antibiotic News and Research RSS Feed - Antibiotic News and Research

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Fewer patients take effective gout drug after steep price increase

Fewer patients take effective gout drug after steep price increase

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price. [More]
Study may point to immediate cause of CF exacerbations

Study may point to immediate cause of CF exacerbations

In the genetic disorder cystic fibrosis (CF), the most severe symptoms are recurring episodes of lung inflammation and bacterial infection (known as "exacerbations") that happen from one to three times a year and cause ever-increasing amounts of lung damage through the course of a CF patient's life. [More]
Mobidiag announces CE-IVD marking and launching of Amplidiag C. difficile+027 test

Mobidiag announces CE-IVD marking and launching of Amplidiag C. difficile+027 test

Mobidiag Ltd, a Finnish molecular diagnostics company specialized in the development of innovative diagnostics solutions for infectious diseases, today announced the launch of Amplidiag C. difficile+027, a qualitative qPCR-based test performed from DNA extracted from stool in suspected cases of C. difficile infection (CDI). [More]
Harry Folk speaks about successful throat cancer treatment received at St. Luke’s Cancer Center

Harry Folk speaks about successful throat cancer treatment received at St. Luke’s Cancer Center

It’s been nine years since Harry Folk of Palmer Township had a scare with throat cancer. He is able to talk about his journey, literally, thanks to the treatment he received at St. Luke’s. The treatment plan recommended by his cancer team not only removed his cancer, but preserved his voice and ability to swallow without difficulty. [More]
Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing. [More]
Outpatient treatments with fewer injections produce similar results to standard treatment course

Outpatient treatments with fewer injections produce similar results to standard treatment course

Giving fewer antibiotic injections to young infants in the developing world with severe infections such as pneumonia and sepsis is just as safe and effective as the standard course of twice daily injections over the course of a week, according to new Johns Hopkins School of Public Health research conducted in Bangladesh. [More]
New approach could help identify novel drug targets to combat lethal fungal infections

New approach could help identify novel drug targets to combat lethal fungal infections

By modifying the CRISPR-Cas genome editing system, Whitehead Institute researchers are now able to manipulate Candida albicans' genome systematically--an approach that could help identify novel targets for therapies against this serious pathogen for which there are a limited number of anti-fungal agents. [More]
Dartmouth researchers use new strategies to target drug-resistant pathogens

Dartmouth researchers use new strategies to target drug-resistant pathogens

By engineering antibacterial enzymes, Dartmouth investigators led by Karl Griswold, PhD are using novel strategies to target the prevalent drug-resistant bacterium Staphylococcus aureus. [More]
International travelers bring multidrug-resistant shigellosis to the US

International travelers bring multidrug-resistant shigellosis to the US

International travelers are bringing a multidrug-resistant intestinal illness to the United States and spreading it to others who have not traveled, according to a report released today by the Centers for Disease Control and Prevention (CDC). [More]
NASH patients more likely to have increased intestinal permeability, shows study

NASH patients more likely to have increased intestinal permeability, shows study

Non-alcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease (NAFLD) that can progress to liver fibrosis and cirrhosis, is associated with leakiness of the intestinal wall, which in turn may worsen liver disease, according to research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association. [More]
MRSA bacteria exposed to cigarette smoke become more resistant to antimicrobial peptides

MRSA bacteria exposed to cigarette smoke become more resistant to antimicrobial peptides

Methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant superbug, can cause life-threatening skin, bloodstream and surgical site infections or pneumonia. Researchers at the University of California, San Diego School of Medicine now report that cigarette smoke may make matters worse. [More]
Hospitals, health systems preparing to treat patients with Ebola face unexpected challenges

Hospitals, health systems preparing to treat patients with Ebola face unexpected challenges

Hospitals and health systems preparing for and treating patients with Ebola Virus Disease (EVD) in the fall of 2015 faced unexpected challenges for ensuring safety of staff, patients and the community. The experiences are detailed in two studies published online in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. [More]

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

The National Institutes of Health has awarded Dr. Walter Fast, associate professor of medicinal chemistry at The University of Texas at Austin's College of Pharmacy, a four-year $2.1 million grant to develop small-molecules that counter antibiotic resistance in Gram-negative bacteria. If successful, the research could lead to new drugs for treating bacterial infections that are resistant to most antibiotics. [More]
China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014. [More]
Drug-resistant E. coli outbreak linked to contaminated endoscopes in Washington state hospital

Drug-resistant E. coli outbreak linked to contaminated endoscopes in Washington state hospital

An outbreak of a novel Escherichia coli (E. coli) strain resistant to antibiotics has been linked to contaminated endoscopes in a Washington state hospital. The study indicates that industry standard cleaning guidelines, which were exceeded by hospital staff, may not be sufficient for sterilizing endoscopes adequately. [More]
Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). [More]
Research: Common bacteria poised to become antibiotic-resistant superbugs

Research: Common bacteria poised to become antibiotic-resistant superbugs

Antibiotic resistance is poised to spread globally among bacteria frequently implicated in respiratory and urinary infections in hospital settings, according to new research at Washington University School of Medicine in St. Louis. [More]
Study finds C. difficile infection increases hospital readmission rates

Study finds C. difficile infection increases hospital readmission rates

Patients with Clostridium difficile infection (CDI) are twice as likely to be readmitted to the hospital as patients without the deadly diarrheal infection, according to a study published in the April issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology. [More]
Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia. [More]
First randomized, controlled trial of pharmacotherapy in PCD patients now in place

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Primary ciliary dyskinesia (PCD) is a rare, genetic respiratory tract disorder leading to progressive pulmonary dysfunction. It exhibits many problems typical for orphan diseases: delayed diagnosis, limited evidence-based knowledge etc. The European Union is funding BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) to introduce uniform guidelines for PCD treatment and diagnosis across Europe. [More]
Advertisement
Advertisement